Abstract
Differentiating the aetiology of thrombocytosis is limited yet crucial in patients with essential thrombocythaemia (ET). MicroRNAs (miRNAs) regulate haematopoiesis and lineage commitment; aberrant expression of miRNAs plays an important role in myeloproliferative neoplasms. However, the miRNA profile has been poorly explored in ET patients compared to patients with reactive thrombocytosis (RT). A total of 9 samples, including 5 ET patient samples, 2 RT patient samples, and 2 healthy control samples, were analysed in this study. We produced 81.43 million reads from transcripts and 59.60 million reads from small RNAs. We generated a comprehensive miRNA-mRNA regulatory network and identified unique 14 miRNA expression patterns associated with ET. Among the 14 miRNAs, miR-1268a was downregulated in ET and showed an inverse correlation with its 8 putative target genes, including genes associated with thrombus formation and platelet activation (CDH6, EHD2, FUT1, KIF26A, LINC00346, PTPRN, SERF1A, and SLC6A9). Principal component analysis (PCA) showed ET and non-ET groups well clustered in space, suggesting each group had a distinctive expression pattern of mRNAs and miRNAs. These results suggest that the significant dysregulation of miR-1268a and its 8 target genes could be a unique expression of platelet mi-RNAs and miRNA/mRNA regulatory network in ET patients.
References
1.
Arber
DA
, Orazi
A
, Hasserjian
R
, Thiele
J
, Borowitz
MJ
, Le Beau
MM
, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
. Blood
. 2016
;127
(20
):2391
–405
. .2.
Wolanskyj
AP
, Schwager
SM
, McClure
RF
, Larson
DR
, Tefferi
A
. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors
. Mayo Clin Proc
. 2006
;81
(2
):159
–66
. .3.
Michiels
JJ
, Berneman
Z
, Schroyens
W
, Koudstaal
PJ
, Lindemans
J
, Neumann
HA
, et al. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia
. Platelets
. 2006
;17
(8
):528
–44
. .4.
Bartel
DP
. MicroRNAs: genomics, biogenesis, mechanism, and function
. Cell
. 2004
;116
(2
):281
–97
. .5.
Sand
M
. The pathway of miRNA maturation
. Methods Mol Biol
. 2014
;1095
:3
–10
. .6.
Benati
M
, Montagnana
M
, Danese
E
, De Matteis
G
, Veneri
D
, Paviati
E
, et al. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms
. Clin Chem Lab Med
. 2015
;53
(7
):1005
–11
. .7.
Zhan
H
, Cardozo
C
, Raza
A
. MicroRNAs in myeloproliferative neoplasms
. Br J Haematol
. 2013
;161
(4
):471
–83
. .8.
Alizadeh
S
, Azizi
SG
, Soleimani
M
, Farshi
Y
, Kashani Khatib
Z
. The role of microRNAs in myeloproliferative neoplasia
. Int J Hematol Oncol Stem Cell Res
. 2016
;10
(3
):172
.9.
Gnatenko
DV
, Dunn
JJ
, McCorkle
SR
, Weissmann
D
, Perrotta
PL
, Bahou
WF
. Transcript profiling of human platelets using microarray and serial analysis of gene expression
. Blood
. 2003
;101
(6
):2285
–93
. .10.
Landry
P
, Plante
I
, Ouellet
DL
, Perron
MP
, Rousseau
G
, Provost
P
. Existence of a microRNA pathway in anucleate platelets
. Nat Struct Mol Biol
. 2009
;16
(9
):961
–6
. .11.
Denis
MM
, Tolley
ND
, Bunting
M
, Schwertz
H
, Jiang
H
, Lindemann
S
, et al. Escaping the nuclear confines: signal-dependent pre-mRNA splicing in anucleate platelets
. Cell
. 2005
;122
(3
):379
–91
. .12.
Stolyar
MA
, Gorbenko
AS
, Olkhovskiy
IA
. Platelet miR-28 expression level and thrombocytosis in MPN patients
. Int J Lab Hematol
. 2019
;41
(2
):e43
–5
. .13.
Xu
X
, Gnatenko
DV
, Ju
J
, Hitchcock
IS
, Martin
DW
, Zhu
W
, et al. Systematic analysis of microRNA fingerprints in thrombocythemic platelets using integrated platforms
. Blood
. 2012
;120
(17
):3575
–85
. .14.
Nagalla
S
, Shaw
C
, Kong
X
, Kondkar
AA
, Edelstein
LC
, Ma
L
, et al. Platelet microRNA-mRNA coexpression profiles correlate with platelet reactivity
. Blood
. 2011
;117
(19
):5189
–97
. .15.
Trapnell
C
, Pachter
L
, Salzberg
SL
. TopHat: discovering splice junctions with RNA-Seq
. Bioinformatics
. 2009
;25
(9
):1105
–11
. .16.
Langmead
B
. Aligning short sequencing reads with Bowtie
. Curr Protoc Bioinformatics
. 2010
;Chapter 11
:Unit 11.7
. .17.
Trapnell
C
, Roberts
A
, Goff
L
, Pertea
G
, Kim
D
, Kelley
DR
, et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks
. Nat Protoc
. 2012
;7
(3
):562
. .18.
Martin
M
. Cutadapt removes adapter sequences from high-throughput sequencing reads
. EMBnet J
. 2011
;17
(1
):10
–2
. .19.
Friedländer
MR
, Mackowiak
SD
, Li
N
, Chen
W
, Rajewsky
N
. miRDeep2 accurately identifies known and hundreds of novel microRNA genes in seven animal clades
. Nucleic Acids Res
. 2011
;40
(1
):37
–52
. .20.
Agarwal
V
, Bell
GW
, Nam
JW
, Bartel
DP
. Predicting effective microRNA target sites in mammalian mRNAs
. Elife
. 2015
;4
:e05005
. .21.
Krüger
J
, Rehmsmeier
M
. RNA hybrid: microRNA target prediction easy, fast and flexible
. Nucleic Acids Res
. 2006
;34
(Web Server Issue
):W451
–4
.22.
De Guire
V
, Robitaille
R
, Tétreault
N
, Guérin
R
, Ménard
C
, Bambace
N
, et al. Circulating miRNAs as sensitive and specific biomarkers for the diagnosis and monitoring of human diseases: promises and challenges
. Clin Biochem
. 2013
;46
(10–11
):846
–60
. .23.
Morin
RD
, O’Connor
MD
, Griffith
M
, Kuchenbauer
F
, Delaney
A
, Prabhu
AL
, et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells
. Genome Res
. 2008
;18
(4
):610
–21
. .24.
Lu
YL
, Yao
JG
, Huang
XY
, Wang
C
, Wu
XM
, Xia
Q
, et al. Prognostic significance of miR-1268a expression and its beneficial effects for post-operative adjuvant transarterial chemoembolization in hepatocellular carcinoma
. Sci Rep
. 2016
;6
:36104
. .25.
Navarro
A
, Pairet
S
, Álvarez-Larrán
A
, Pons
A
, Ferrer
G
, Longarón
R
, et al. miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia
. Blood Cancer J
. 2016
;6
:e406
. .26.
Zhao
L
, Wu
S
, Huang
E
, Gnatenko
D
, Bahou
WF
, Zhu
W
. Integrated micro/messenger RNA regulatory networks in essential thrombocytosis
. PLoS One
. 2018
;13
(2
):e0191932
. .27.
Barroga
CF
, Pham
H
, Kaushansky
K
. Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression
. Exp Hematol
. 2008
;36
(12
):1585
–92
. .28.
Bruchova
H
, Merkerova
M
, Prchal
JT
. Aberrant expression of microRNA in polycythemia vera
. Haematologica
. 2008
;93
(7
):1009
–16
. .29.
Dore
LC
, Amigo
JD
, Dos Santos
CO
, Zhang
Z
, Gai
X
, Tobias
JW
, et al. A GATA-1-regulated microRNA locus essential for erythropoiesis
. Proc Natl Acad Sci U S A
. 2008
;105
(9
):3333
–8
. .30.
Bijak
M
, Dzieciol
M
, Rywaniak
J
, Saluk
J
, Zielinska
M
. Platelets miRNA as a prediction marker of thrombotic episodes
. Dis Markers
. 2016
;2016
:2872507
. .31.
Sonoda
T
, Matsuzaki
J
, Yamamoto
Y
, Sakurai
T
, Aoki
Y
, Takizawa
S
, et al. Serum microRNA-based risk prediction for stroke
. Stroke
. 2019
;50
(6
):1510
–8
. .32.
Scanlon
VM
, Teixeira
AM
, Tyagi
T
, Zou
S
, Zhang
PX
, Booth
CJ
, et al. Epithelial (E)-cadherin is a novel mediator of platelet aggregation and clot stability
. Thromb Haemost
. 2019
;119
(5
):744
–57
.33.
Senis
YA
. Protein-tyrosine phosphatases: a new frontier in platelet signal transduction
. J Thromb Haemost
. 2013
;11
(10
):1800
–13
. .34.
Tsang
J
, Zhu
J
, Van Oudenaarden
A
. MicroRNA-mediated feedback and feedforward loops are recurrent network motifs in mammals
. Mol Cell
. 2007
;26
(5
):753
–67
. .© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
